Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more
Cybin Inc (CYBN) - Total Liabilities
Latest total liabilities as of September 2025: $42.25 Million USD
Based on the latest financial reports, Cybin Inc (CYBN) has total liabilities worth $42.25 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cybin Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Cybin Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cybin Inc Competitors by Total Liabilities
The table below lists competitors of Cybin Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The RMR Group Inc
F:26R
|
Germany | €272.28 Million |
|
Eugene Inv&Sec
KO:001200
|
Korea | ₩9.14 Trillion |
|
ANY Security Printing PLC
BUD:ANY
|
Hungary | Ft31.38 Billion |
|
Ho Tung Chemical Corp
TW:1714
|
Taiwan | NT$6.89 Billion |
|
Net Lease Office Properties
NYSE:NLOP
|
USA | $88.33 Million |
|
Raymond Lifestyle Ltd
NSE:RAYMONDLSL
|
India | ₹45.70 Billion |
|
Warpaint London PLC
OTCQX:WPNTF
|
USA | $31.72 Million |
|
Zhejiang Zomax Transmission
SHG:603767
|
China | CN¥290.62 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Cybin Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cybin Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cybin Inc (2017–2025)
The table below shows the annual total liabilities of Cybin Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $21.42 Million | +112.14% |
| 2024-03-31 | $10.10 Million | +27.67% |
| 2023-03-31 | $7.91 Million | +31.93% |
| 2022-03-31 | $5.99 Million | +2179.09% |
| 2021-03-31 | $263.00K | 0.00% |
| 2020-03-31 | $263.00K | +1826.32% |
| 2019-03-31 | $13.65K | -14.30% |
| 2018-03-31 | $15.93K | -89.40% |
| 2017-03-31 | $150.29K | -- |